Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional studyE Tartour, J Y Blay, T Dorval, et al.
Clinical and Experimental Immunology|December 22, 1999
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patientsN Haicheur, B Escudier, T Dorval, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settingsJ Beck, G Procopio, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2014
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trialS Leyvraz, S Piperno-Neumann, S Suciu, et al.
British Journal of Cancer|July 14, 2011
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studiesT Eisen, R Marais, A Affolter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1997
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapyP Rougier, R Bugat, J Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trialT K Choueiri, K Penkov, H Uemura, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 5